Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iterum Therapeutics Plc (NQ: ITRM )

1.625 +0.015 (+0.92%)
Streaming Delayed Price Updated: 9:59 AM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iterum Therapeutics Plc

< Previous 1 2 3 4 5 6 7 8 9 Next >
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q1 2024
ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023
ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Iterum Therapeutics's Earnings: A Preview
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Recap: Iterum Therapeutics Q3 Earnings
Via Benzinga
Earnings Outlook For Iterum Therapeutics
Via Benzinga
Iterum Therapeutics's Earnings: A Preview
Via Benzinga
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why Iterum Therapeutics Stock Is Trending Today
Iterum Therapeutics announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Insiders Buying Iterum Therapeutics And 3 Other Stocks Under $3
The Dow Jones index closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Iterum Therapeutics PLC (NASDAQ: ITRM) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Earnings Scheduled For August 11, 2023
Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Iterum Therapeutics Reports Employment Inducement Grant
From Iterum Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
From Iterum Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
From Iterum Therapeutics plc
Via GlobeNewswire
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022
From Iterum Therapeutics plc
Via GlobeNewswire
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
From Iterum Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.